丙型肝炎治疗市场：依药物类别、给药途径、通路及地区划分

丙型肝炎治疗市场规模预计将从 2023 年的 86 亿美元增加到 2030 年的 113.9 亿美元，预测期内复合年增长率为 4.1%。

图 1. 2023 年按地区分類的C型肝炎药物全球市场占有率(%)

丙型肝炎是一种肝臟感染疾病，会导致严重的肝损伤。它是由C型肝炎病毒引起的。美国约有 240 万人受到影响。然而，丙型肝炎很少引起症状，因此大多数人不会注意到任何症状。该病毒透过感染者的血液和体液传播。

丙型肝炎潜伏期。这是从第一次接触到发病的时期。潜伏期为14至80天，但平均为45天。急性C型肝炎：这是一种短期疾病，病毒进入体内后会持续 6 个月。然后，有些人能够自行消灭病毒。慢性C型肝炎：大多数感染C型肝炎的人（高达 85%）会进入长期患病阶段（超过 6 个月）。这称为慢性C型肝炎感染，可导致肝癌和肝硬化等严重的健康问题。肝硬化。这种疾病会引起发炎，随着时间的推移，健康的肝细胞会被疤痕组织所取代。发展为肝硬化通常需要大约 20 至 30 年的时间，但饮酒或感染 HIV 可能会更快导致肝硬化。

市场动态：

全球丙型肝炎盛行率的上升预计将在预测期内促进市场成长。例如，根据国家生物技术资讯中心2021年9月18日发布的资料，印度HCV盛行率为0.5%，影响约470万至1,090万人。

第一章 研究目的与前提

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

• 市场动态
  • 促进因素
• 全球丙型肝炎盛行率不断上升
• 政府加大力度
  • 抑制因素
• 负面影响增加
  • 机会
• 增加不同地区的产品供应
• 影响分析
• 主要亮点
• 监管场景
• 产品发布/核准
• PEST分析
• 波特的分析
• 併购场景

第四章丙型肝炎治疗药物市场 -冠状病毒（COVID-19）大流行的影响

• 新型冠状病毒感染疾病（COVID-19）的流行病学
• 供需面分析
• 经济影响

第五章丙型肝炎药物市场，依药物类别，2018-2030

• NS3/4A蛋白酶抑制剂
• NS5A抑制剂
• NS5B聚合酶抑制剂
• 组合药物
• 其他的

第六章 2018-2030 年C型肝炎治疗药物市场（依给药途径）

• 口服
• 静脉
• 其他的

第七章 2018-2030 年C型肝炎治疗药物市场（依通路）

• 医院药房
• 零售药房
• 网路药房

第八章 2018-2030 年C型肝炎治疗药物市场（按地区）

• 北美洲
• 美国
• 加拿大
• 欧洲
• 英国
• 德国
• 法国
• 义大利
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 中国
• 日本
• 印度
• 澳洲
• ASEAN
• 韩国
• 其他亚太地区
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲
• 中东
• GCC
• 以色列
• 其他中东地区
• 非洲
• 南非
• 北非
• 中部非洲

第9章 竞争形势

• Gilead Sciences
• AbbVie
• Merck & Co
• Bristol-Myers Squibb
• Johnson & Johnson
• Hoffmann-La Roche AG
• Boehringer Ingelheim
• Achillion Pharmaceuticals

第10章

• 调查方法
• 关于出版商

The hepatitis C drugs market size is expected to reach US$ 11.39 billion by 2030, from US$ 8.60 billion in 2023, growing at a CAGR of 4.1% during the forecast period.

Figure 1. Global Hepatitis C Drugs Market Share (%), by Region, 2023

Hepatitis C is a liver infection that can lead to serious liver damage. It's caused by the hepatitis C virus. About 2.4 million people in the U.S. have the disease. But it causes few symptoms, so most of them don't know. The virus spreads through an infected person's blood or body fluids.

Stages of Hepatitis C: Incubation period. This is the time between first exposures to the start of the disease. It can last anywhere from 14 to 80 days, but the average is 45. Acute hepatitis C. This is a short-term illness that lasts for the first 6 months after the virus enters your body. After that, some people who have it will get rid of, or clear, the virus on their own. Chronic hepatitis C. For most people who get hepatitis C - up to 85% - the illness moves into a long-lasting stage (longer than 6 months). This is called a chronic hepatitis C infection and can lead to serious health problems like liver cancer or cirrhosis. Cirrhosis. This disease leads to inflammation that, over time, replaces your healthy liver cells with scar tissue. It usually takes about 20 to 30 years for this to happen, though it can be faster if you drink alcohol or have HIV.

Market Dynamics:

The increasing prevalence of hepatitis C globally is expected to aid in the market growth over the forecast period. For instance, according to the data published by the National Center for Biotechnology Information on September 18, 2021, the prevalence rate of HCV in India is 0.5%, affecting about 4.7 to 10.9 million people.

Hepatitis C Drugs Market Segmentation:

• By Drug Class
  • NS3/4A Protease Inhibitors
  • NS5A Inhibitors
  • NS5B Polymerase Inhibitors
  • Combination Drugs
  • Others
• By Route of Administration
  • Oral Drugs
  • Intravenous
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Top Companies in Hepatitis C Drugs Market:
  • Gilead Sciences
  • AbbVie
  • Merck & Co
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Hoffmann-La Roche AG
  • Boehringer Ingelheim
  • Achillion Pharmaceuticals

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
• Growing Prevalence of Hepatitis C Globally
• Increasing Government Initiatives
  • Restraints
• Increasing Adverse Effects
  • Opportunities
• Increasing Product Availability in Various Regions
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Hepatitis C Drugs Market- Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Hepatitis C Drugs Market, By Drug Class, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019 - 2030
  • Segment Trends
• NS3/4A Protease Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• NS5A Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• NS5B Polymerase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Combination Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

6. Hepatitis C Drugs Market, By Route of Administration, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023and 2030 (%)
  • Y-o-Y Growth Analysis, 2019- 2030
  • Segment Trends
• Oral Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

7. Hepatitis C Drugs Market, By Distribution Channel, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023and 2030 (%)
  • Y-o-Y Growth Analysis, 2019- 2030
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

8. Hepatitis C Drugs Market, By Region, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, By Country, 2023and 2030 (%)
  • Y-o-Y Growth Analysis, For Country 2019-2030
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• U.S.
• Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• U.K.
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• China
• Japan
• India
• Australia
• ASEAN
• South Korea
• Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• South Africa
• North Africa
• Central Africa

9. Competitive Landscape

• Gilead Sciences
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Merck & Co
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Hoffmann-La Roche AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Boehringer Ingelheim
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Achillion Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Analyst Views

10. Section

• Research Methodology
• About us